INTCO MEDICAL(SZ:300677) Sou Hu Cai Jing·2025-10-20 16:30Core Viewpoint - The company, Yingke Medical, has reported a decline in stock price and significant changes in its capital structure, alongside key developments in its incentive plans and investment activities [1][2][3]. Trading Information Summary - On October 20, 2025, Yingke Medical's stock closed at 42.01 yuan, down 2.21%, with a turnover rate of 6.49% and a trading volume of 301,700 hands, resulting in a transaction amount of 1.261 billion yuan [1]. - The net outflow of main funds was 52.69 million yuan, while retail investors saw a net inflow of 39.54 million yuan [1][4]. Shareholder and Capital Changes - The company has repurchased and canceled 410,480 shares of restricted stock, and the conversion of some convertible bonds has led to an increase in registered capital from 641.700369 million yuan to 654.383263 million yuan [1][2][4]. - The total number of shares has increased from 641.700369 million to 654.383263 million [1][2]. Performance Disclosure Highlights - For the year 2024, the company reported an operating income of 9.523 billion yuan and a net profit of 1.167 billion yuan, meeting the performance assessment requirements for the third phase of the 2022 restricted stock incentive plan [2]. - The third phase of the 2022 restricted stock incentive plan has been approved for release from restrictions, involving 540 incentive targets and a total of 1,052,520 shares [2][3]. Institutional Research Highlights - The company's wholly-owned subsidiary plans to invest 70 million USD in Warburg Pincus Global Growth 15, L.P., which constitutes a related party transaction [2][4]. - The board of directors has proposed to hold the sixth extraordinary general meeting of shareholders in 2025 on November 5, 2025, to review related proposals [3].